Get the Stockscreener App
11.22
2.43%
-0.28
After Hours:
11.20
-0.02
-0.18%
4 D Molecular Therapeutics Inc stock is traded at $11.22, with a volume of 997.53K.
It is down -2.43% in the last 24 hours and up +31.23% over the past month.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$11.50
Open:
$11.6
24h Volume:
997.53K
Relative Volume:
0.77
Market Cap:
$524.00M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-4.218
EPS:
-2.66
Net Cash Flow:
$-78.56M
1W Performance:
-8.56%
1M Performance:
+31.23%
6M Performance:
+198.40%
1Y Performance:
+38.60%
1-Day Range:
$10.60
$11.70
1-Week Range:
$10.60
$12.34
52-Week Range:
$2.235
$12.34
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
11.22 | 537.08M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-21-24 | Initiated | Morgan Stanley | Underweight |
| Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Apr-15-24 | Initiated | Barclays | Overweight |
| Feb-07-24 | Resumed | Goldman | Buy |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-22-22 | Initiated | Jefferies | Buy |
| Jan-04-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Evercore ISI | Outperform |
| Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
Applying big data sentiment scoring on 4D Molecular Therapeutics Inc.Options Play & Free Expert Verified Stock Movement Alerts - newser.com
Backtesting results for 4D Molecular Therapeutics Inc. trading strategiesTrade Analysis Summary & Safe Swing Trade Setups - newser.com
Why 4D Molecular Therapeutics Inc. stock remains on watchlistsDollar Strength & Weekly Top Performers Watchlists - newser.com
Is 4D Molecular Therapeutics Inc. stock ready for a breakoutMarket Activity Recap & Entry Point Confirmation Alerts - newser.com
4D Molecular Therapeutics Partners with Otsuka for APAC Market - MSN
4D Molecular Therapeutics (FDMT) Stock: Soars on $85M Otsuka Deal to Expand 4D-150 Across APAC - parameter.io
4D Molecular Shares Rise Premarket on Partnership With Otsuka - MarketScreener
4D Molecular (FDMT) Forms Key Partnership with Otsuka Pharmaceutical - GuruFocus
FDMT licenses 4D-150 in APAC to Otsuka with $85M upfront - Stock Titan
4D Molecular Therapeutics, Inc. Enters into Collaboration and License Agreement with Otsuka Pharmaceutical Co., Ltd - MarketScreener
4D Molecular Therapeutics Announces Strategic Partnership with Otsuka Pharmaceutical Co. Ltd. to Develop and Commercialize 4D-150 for Treatment of Wet AMD and DME in APAC Region Including Japan - MarketScreener
4D Molecular Therapeutics Announces Strategic Partnership with Otsuka for Development of 4D-150 in Asia-Pacific Markets - Quiver Quantitative
4DMT (NASDAQ: FDMT) licenses 4D-150 to Otsuka in APAC; $85M upfront, $336M milestones - Stock Titan
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific - Yahoo Finance
How institutional ownership impacts 4D Molecular Therapeutics Inc. stockTreasury Yields & Daily Chart Pattern Signal Reports - newser.com
4D Molecular Therapeutics, Inc. (FDMT) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
4D Molecular Therapeutics, Inc. (FDMT) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
4D Molecular Therapeutics Advances Gene Therapy Trial for Fabry Disease - MSN
4D Molecular Therapeutics Advances Phase 3 Trial for Vision Loss Treatment - MSN
4D Molecular Therapeutics Advances in Macular Degeneration Treatment: A Phase 3 Study Update - MSN
4D Molecular Therapeutics Appoints New Financial Officer - MSN
Will 4D Molecular Therapeutics Inc. stock see insider buying2025 Stock Rankings & Proven Capital Preservation Methods - fcp.pa.gov.br
What is the fair value of 4D Molecular Therapeutics Inc. stock now2025 Biggest Moves & AI Driven Stock Reports - newser.com
4D Molecular Therapeutics Executive Sells Shares - TradingView
FDMT insider trade: options at $6.49, sale at $12 on 10/24/2025 - Stock Titan
4D Molecular Therapeutics Advances Gene Therapy for Wet AMD - TipRanks
4D Molecular Therapeutics Advances Gene Therapy Trial for Cystic Fibrosis - TipRanks
4D Molecular Therapeutics Secures Up to $11M More from CF Foundation to Accelerate 4D-710 Development - Insider Monkey
4D Molecular Therapeutics’ (FDMT) “Outperform” Rating Reiterated at Royal Bank Of Canada - Defense World
Can 4D Molecular Therapeutics Inc. stock resist sector downturnsWeekly Profit Report & Free Real-Time Volume Trigger Notifications - newser.com
RBC Capital Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT) - The Globe and Mail
RBC Capital Reiterates 4D Molecular Therapeutics (FDMT) Outperform Recommendation - Nasdaq
What recovery options are there for 4D Molecular Therapeutics Inc.Risk Management & Expert Approved Momentum Trade Ideas - newser.com
How to build a dashboard for 4D Molecular Therapeutics Inc. stockOptions Play & Free Expert Verified Stock Movement Alerts - newser.com
Bizily, 4D Molecular Therapeutics CLO, sells $16,627 in FDMT stock - Investing.com India
Bizily, 4D Molecular Therapeutics CLO, sells $16,627 in FDMT stock By Investing.com - Investing.com Nigeria
4D Molecular Therapeutics insider trade under 10b5-1 plan - Stock Titan
Wall Street Analysts See a 208.52% Upside in 4D Molecular Therapeutics (FDMT): Can the Stock Really Move This High? - MSN
Does 4D Molecular Therapeutics Inc. stock trade at a discount to peers2025 Pullback Review & Reliable Momentum Entry Alerts - nchmf.gov.vn
Will 4D Molecular Therapeutics Inc. stock benefit from AI adoption2025 Top Gainers & Real-Time Chart Pattern Alerts - nchmf.gov.vn
Leerink Partnrs Issues Optimistic Estimate for FDMT Earnings - Defense World
How 4D Molecular Therapeutics Inc. stock responds to policy changesTrade Volume Report & Free Growth Oriented Trading Recommendations - Trung tâm Dự báo KTTV quốc gia
4DMT Announces New Employment Inducement Grants - GlobeNewswire
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):